Shuttle Pharmaceuticals (SHPH) Stock Price, News & Analysis

Company Overview

Shuttle Pharmaceuticals Holdings, Inc., a clinical stage pharmaceutical company, develops novel therapies to cure cancers. It develops Ropidoxuridine, an oral halogenated pyrimidine to treat patients with brain tumors and sarcomas SP-1-161, an HDAC inhibitor that initiates the mutated in ataxia-telangiectasia response pathway for radiation sensitizing cancer cells and protecting normal cells; SP-2-225, a pre-clinical class IIb that effects on the regulation of the immune system; and SP-1-303, a pre-clinical selective Class I HDAC for the treatment of ER positive cancers . The company is based in Gaithersburg, Maryland.

Key Stats

• Today's Range: $0.84 to $0.92
• 50-Day Range: $0.61 to $1.15
• 52-Week Range: $0.58 to $4.71
• Volume: 33,523 shs
• Average Volume: 60,885 shs
• Market Capitalization: $3.59 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

Shuttle Pharmaceuticals Stock Analysis - MarketRank™

Shuttle Pharmaceuticals scored higher than 13% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: N/A
• Analyst Rating: N/A

Consensus Rating

There is not enough analysis data for Shuttle Pharmaceuticals.

Earnings and Valuation

• Score: 0.6 / 5
• Proj. Earnings Growth: N/A

Price to Earnings Ratio vs. the Market

The P/E ratio of Shuttle Pharmaceuticals is -0.21, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Shuttle Pharmaceuticals is -0.21, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

Shuttle Pharmaceuticals has a P/B Ratio of 0.43. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

Short Interest

• Score: 3.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

1.24% of the float of Shuttle Pharmaceuticals has been sold short.

Short Interest Ratio / Days to Cover

Shuttle Pharmaceuticals has a short interest ratio ("days to cover") of 0, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Shuttle Pharmaceuticals has recently increased by 1,312.50%, indicating that investor sentiment is decreasing significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Shuttle Pharmaceuticals does not currently pay a dividend.

Dividend Growth

Shuttle Pharmaceuticals does not have a long track record of dividend growth.

Sustainability and ESG

• Score: N/A
• Environmental Score: N/A

Percentage of Shares Shorted

1.24% of the float of Shuttle Pharmaceuticals has been sold short.

Short Interest Ratio / Days to Cover

Shuttle Pharmaceuticals has a short interest ratio ("days to cover") of 0, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Shuttle Pharmaceuticals has recently increased by 1,312.50%, indicating that investor sentiment is decreasing significantly.

News and Social Media

• Score: 1.1 / 5
• News Sentiment: N/A

Search Interest

1 people have searched for SHPH on MarketBeat in the last 30 days.

MarketBeat Follows

1 people have added Shuttle Pharmaceuticals to their MarketBeat watchlist in the last 30 days.

Company Ownership

• Score: 1.7 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Shuttle Pharmaceuticals insiders have not sold or bought any company stock.

Percentage Held by Insiders

39.60% of the stock of Shuttle Pharmaceuticals is held by insiders. A high percentage of insider ownership can be a sign of company health.

Percentage Held by Institutions

Only 4.58% of the stock of Shuttle Pharmaceuticals is held by institutions.

SHPH Stock Analysis - Frequently Asked Questions

How have SHPH shares performed this year?

Shuttle Pharmaceuticals' stock was trading at $0.8590 on January 1st, 2025. Since then, SHPH stock has increased by 2.4% and is now trading at $0.88.
View the best growth stocks for 2025 here.

When did Shuttle Pharmaceuticals IPO?

Shuttle Pharmaceuticals (SHPH) raised $10 million in an initial public offering (IPO) on Wednesday, August 31st 2022. The company issued 1,225,888 shares at $8.13 per share.

How do I buy shares of Shuttle Pharmaceuticals?

Shares of SHPH stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of Shuttle Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Shuttle Pharmaceuticals investors own include Mullen Automotive (MULN), MSP Recovery (LIFW), MSP Recovery (LIFW), NIO (NIO), Tesla (TSLA), Broadcom (AVGO) and AMTD Digital (HKD).

Company Calendar

• Today: 1/21/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: Pharmaceutical preparations
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:SHPH
• CUSIP: N/A
• CIK: 1757499
• Web: www.shuttlepharma.com
• Phone: 240-403-4212
• Fax: N/A
• Employees: 5
• Year Founded: N/A

Profitability

• EPS (Most Recent Fiscal Year): ($4.15)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: $-6,590,000.00
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: -583.02%
• Return on Assets: -258.92%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 0.22
• Quick Ratio: 0.22

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $2.03 per share
• Price / Book: 0.42

Miscellaneous

• Outstanding Shares: 4,080,000
• Free Float: 2,463,000
• Market Cap: $3.50 million
• Optionable: Not Optionable
• Beta: -1.74